Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results forGSK
1,478.92
+4.92 (0.33%)
Sep 25 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,463.59 - 1,480.50
52 week 1,444.00 - 1,745.56
Open 1,469.00
Vol / Avg. 5.27M/5.98M
Mkt cap 72,741.10M*
P/E 37.49
Div/yield 19.00*
EPS 0.39*
Shares 4,918.52M
Beta     -
Inst. own     -
*GBP
Oct 25, 2017
Q3 2017 GlaxoSmithKline PLC Earnings Release Add to calendar
Sep 7, 2017
GlaxoSmithKline PLC Exercises Option Over Adaptimmune Therapeutics PLC's SPEAR T-cell Therapy Program Targeting NY-ESO Call - Webcast
Sep 7, 2017
GlaxoSmithKline PLC at Wells Fargo Healthcare Conference
Jul 26, 2017
Q2 2017 GlaxoSmithKline PLC Earnings Call - Webcast
Jul 26, 2017
Q2 2017 GlaxoSmithKline PLC Earnings Release
Jul 19, 2017
Emergent BioSolutions Inc to Discuss Acquisition of Raxibacumab from GlaxoSmithKline PLC Conference Call - Webcast
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -1.17% 3.81%
Operating margin 0.00% 9.32%
EBITD margin - 33.06%
Return on average assets -0.59% 1.89%
Return on average equity -57.19% 29.24%
Employees 99,827 -
CDP Score - A

Address

980 Great West Road
BRENTFORD, TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Officers and directors

Emma Walmsley Chief Executive Officer - Designate, Executive Director
Age: 46
Simon Dingemans Chief Financial Officer, Executive Director
Age: 52
Patrick Vallance President - Pharmaceuticals R&D, Executive Director
Roger Connor President - Global Manufacturing & Supply
Abbas Hussain President - Global Pharmaceuticals
Shah Abbas Hussain President - Global Pharmaceuticals
Luke Miels President - Global Pharmaceuticals
Daniel E Troy Senior Vice President, General Counsel
Claire Thomas Senior Vice President - Human Resources
Nick Hirons Senior Vice President – Global Ethics and Compliance